When comparing the mutations identified in the NSCLC and SCLC groups, we observed that RB1 was depicted with a higher number of different mutations in tumor samples and this gene was altered in a higher number of patients in the SCLC group (Figure 7); this result was consistent with the TCGA data analysis (Figure 2). The gene discussed is RB1; the disease is neoplasm.